Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, trastuzumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., HER2 binding specificity), for the purpose of providing cancer (e.g., HER2-related cancer) treatments in a subject in need thereof.

Abstract: This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, by reducing chemotherapy-related toxicity to a level that allows the chemotherapeutic drug to be used in humans.

Abstract: This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

Abstract: This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, including, for example, reducing chemotherapy-related toxicity (e.g., liver toxicity).

Abstract: The invention described herein relates to methods for treating a patient having a plurality of HLA-negative cancer cells or cancer cells with reduced HLA expression with IFN-alpha in an amount sufficient to expand and/or activate immune cells such that the activated and/or expanded immune cells kill one or more of HLA-negative cancer cells or the cancer cells with reduced HLA expression.

Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells and administering a PD-1 inhibitor to such a mammal are provided.

Abstract: In one implementation, a computer-implemented method includes accessing patient-derived blood data; identifying biomarker pair interactions based on signal processing of the patient-derived blood data; generating a data model that characterizes one or more aspects of human immune system interactions based on reverse engineering of the human immune system interactions using the identified biomarker pair interactions; evaluating suitability of the data model, wherein the evaluating includes: statistically testing the data model in characterizing correlations between biomarker pairs; decomposing the data model to determine (i) model order accuracy, (ii) whether biomarker nodes act in together or opposite each other, and (iii) normalized data with dynamic effects of and providing the data model for use in treatment-based decision making based on the evaluating.

Abstract: A system and method determines one or more favorable dates for delivery of therapeutic treatment to a specific patient based on the “state” of one or more biological variables of the patient on the proposed treatment date(s). The “state” of the biological variables refers to whether the concentration of the biological variable is greater than a threshold value (state=HIGH or UP) on the proposed date of treatment or less than a threshold value (state=LOW or DOWN) on the proposed date of treatment. The biological variables may include lymphocytes and/or monocytes. A system and method may also determine one or more favorable dates for delivery of therapeutic treatment to patient based on a lymphocyte-to-monocyte ratio on the proposed treatment dates, and/or the “state” of the lymphocytes and monocytes on the proposed treatment dates.

Abstract: Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for predicting and improving survival based on the absolute number of natural killer cells observed in the subject after transplant.

Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described are stable nanoparticle complexes of 100 nm to 900 nm comprising paclitaxel, albumin and a polypeptide which binds CD20 (such as rituximab). The complexes are suitable for the treatment of cancer, including lymphoma.

Abstract: Disclosed herein are improved compositions and methods involved in treating hematologic cancers, i.e., cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. The compositions comprise complexes containing albumin-containing nanoparticles (e.g., ABRAXANE® nanoparticles) and antibodies. The compositions are used to effect hematologic cancer cell death.

Abstract: This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.

Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses HER2.

Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52.

Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses VEGF.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.